Ten genes (namely, ADAMTS12, CCDC181, CD44, EPAS1, FILIP1L, KCTD8, NAALAD2, NEK9, PRKCB, and ZMIZ1) were selected for further validation in 151 PCa, 51 NPT, and 17 BPH samples (Table S2), based on the methylation differences in promoter regions according to prostate tissue histology (ADAMTS12, CCDC181, CD44, FILIP1L, KCTD8, NAALAD2, PRKCB, ZMIZ1) or BCR status (EPAS1, FILIP1L, NEK9, PRKCB, ZMIZ1). The gene discussed is NAALAD2; the disease is benign prostatic hyperplasia.